Evaxion receives nasdaq notification regarding minimum bid price deficiency

Copenhagen, denmark, oct. 05, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, announced today that the company received a letter (the “notification letter”) on september 29, 2023 from the listings qualifications department of the nasdaq stock market llc (“nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the company's american depositary shares (“adss”) had closed below the minimum $1.00 per share requirement for continued listing on the nasdaq global market under nasdaq listing rule 5550(a)(2). in accordance with nasdaq listing rule 5810(c)(3)(a), the company has been provided an initial period of 180 calendar days, or until march 27, 2024, to regain compliance.
EVAX Ratings Summary
EVAX Quant Ranking